Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Overview of attention for article published in Clinical Breast Cancer, August 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 1 X post from an account with 516 followers.

Original Study: A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-Negative Breast Cancer https://t.co/peJmkyiDLo https://t.co/e34IjUTqVW

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.